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Mastitis, a mammary gland inflammation in response to bacterial
infection, is a major problem in the dairy industry. We found that
cows susceptible to mastitis have a three-base insertion in a
glycine-coding stretch of the gene for forebrain embryonic zinc
finger-like (FEZL), a transcription factor with a role in neuronal
development. Mastitis induces FEZL expression in mammary
glands, and induced FEZL promotes expression of the axon-attract-
ing molecule semaphorin 5A (SEMA5A) through a GCAG sequence.
FEZL also induces SEMA5A expression in susceptible cattle but at a
lower level than in resistant cattle. Enhanced SEMA5A induces
expression of at least nine genes related to the host’s immune
response, including TNF- and IL-8. We propose that susceptibility
to mastitis results from an impaired immune response due to the
lower transcription activity of susceptible FEZL. Our results provide
an avenue to select for genetic improvement of resistance to
mastitis and suggest that the FEZL–SEMA5A pathway might con-
trol both neuronal development and innate immunity.
FEZL  quantitative trait locus  semaphorin 5A
Mastitis generates annual total losses of 69 billion yen inJapan (1) and 2 billion dollars in the United States (2) by
reducing milk quantity and quality and increasing health costs.
Just as current selective breeding programs based on population
genetics have successfully increased milk yield, genetic selection
for mastitis resistance could potentially be practiced, not only to
reduce the cost of producing milk but also to improve the health
and well-being of dairy cows. Recently Wall et al. (3) produced
transgenic cows resistant to infection by inducing the cells of the
mammary gland to secret an antibacterial protein. However, the
public may not quickly accept milk from transgenic animals
despite the improved health of dairy herds (4). On the other
hand, several groups have begun quantitative trait locus (QTL)
mapping using a granddaughter design to identify genes influ-
encing mastitis resistance (e.g., ref. 2). Alternatively, we used six
half-sibling families whose sires were derived from the same
grandsire and performed selective genotyping. This method
reduces the number of progeny genotyped, although phenotypic
effects may be overestimated because of the biased selection of
progeny (e.g., ref. 5). The function of a gene carrying a putative
polymorphism positionally identified should significantly influ-
ence the phenotype.
Forebrain embryonic zinc finger-like (FEZL) (6) controls the
development of monoaminergic neurons (7). Hirata et al. (8)
reported that FEZL-deficient mice display hyperactive behavior,
suggesting that FEZL has a role in neuronal development.
Semaphorin 5A (SEMA5A), an axon guidance cue (9), belongs
to the semaphorin family characterized by functionally con-
served roles in neuronal development (10). Recent studies,
however, revealed the existence of crosstalk between neuronal
development and immunity. The neuronal repellent Slit regu-
lates both neuronal and leukocyte migration (11). The sema-
phorin family members SEMA4A and SEMA4D activate T cells
(12) and enhance B cell responses (13), respectively. Kumanogoh
et al. (12, 13) called them ‘‘immune semaphorins,’’ but it is not
known whether SEMA5A is an immune semaphorin.
We demonstrate here that susceptible cows have a three-base
insertion in the FEZL gene. Mastitis enhances FEZL, FEZL
promotes SEMA5A, and SEMA5A induces TNF- and IL-8
expression. Because the resistant FEZL allele promotes higher
SEMA5A expression than the susceptible FEZL allele, the
susceptibility to mastitis might result from impaired immune
response. Here we identify a gene influencing mastitis resistance
at the molecular level and outline an unexpected role for the
FEZL–SEMA5A signaling pathway in innate immunity.
Results
A Somatic Cell Score (SCS) Locus Is Linked to FEZL. To determine
QTL influencing mastitis resistance, we selected six half-sibling
families with a total of 6,561daughters in the Tokachi county
area of Hokkaido, Japan, to minimize possible environmental
variations. We used the average SCS [log2 (somatic cell count
100)  3] during the first lactation period as a phenotype
parameter, because there is a strong genetic correlation between
SCS and mastitis (14). The somatic cell count in milk did not
normally distribute, whereas SCS did (skewness  0.93; kurto-
sis0.42; Fig. 5, which is published as supporting information
on the PNAS web site). We attempted to collect cows with SCS
of 5, suspected to have clinical mastitis (15); however, most of
them had been culled. The resulting families consisted of 181
daughters with high SCS of 4.82 and 297 daughters with low SCS
of 0.65 (Table 1).
With our 478 samples, we embarked on a whole-genome scan
of 29 autosomal chromosomes by typing 272 microsatellite
markers. The analysis using the DISMULT program of the DISEQ
package, which is suitable for a multipoint analysis of selective
genotyping data, revealed significant linkage of SCS loci to Bos
taurus autosomal chromosomes BTA21 and BTA22 with a
likelihood of odds (LOD) score of5 (Fig. 6, which is published
as supporting information on the PNAS web site). Further
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analysis with an additional 64 markers in BTA22 supported the
linkage (Fig. 1A), although the LOD scores by DISEQ are likely
overestimates because all pedigrees were related. We also con-
firmed significant linkage as an F-statistic of 4.45 (P  0.01) in
a total of 6,561 daughters of the families using QTLEXPRESS,
which was developed for the analysis of QTL from outbred
populations and was able to include the phenotype information
of untyped samples (Fig. 1A). Next we assumed that the 6.2-
centimorgan interval with a LOD score of 18 by DISEQ is
critical for SCS, and we constructed a bacterial artificial chro-
mosome contig containing the region (Fig. 1B). Partial sequenc-
ing of the contig indicated that the 6.2-centimorgan region was
equivalent to Homo sapiens autosomal chromosome 3p14.2,
where six known genes were assigned (ref. 16 and Fig. 1B).
We determined phase of the 6.2-centimorgan region in 478
daughters using four microsatellites and found that Sire 4 had
susceptible (S) alleles whereas the remaining sires had resistant
(R) alleles, suggesting that Walkway Chief Mark, a grandsire of
our families, would have been heterozygous (Fig. 2). Sequencing
exons of the six genes in three cows having homozygous R alleles
with low SCS and three cows having homozygous S alleles with
high SCS, we identified neither nonsense nor missensemutations
except for a three-base insertion in the FEZL S allele. FEZL
contains six C2H2 type zinc-finger domains and a glycine stretch
where the insertion resulted in an extension of 12 glycine (12G)
to 13 glycine (13G) (Fig. 7, which is published as supporting
information on the PNAS web site). Although we cannot exclude
the possibility that one or more of the other five genes may affect
SCS, it is valuable to examine whether the polymorphism in
FEZL affects SCS.
In our half-sibling families born during 1990–1996, 8.7% of
12G12G FEZL cattle had SCS of 5, whereas 17.0% of
13G13G FEZL cattle did (Table 2), suggesting that 13G13G
FEZL cattle have twice the rate of susceptibility to mastitis than
12G12G FEZL cattle. Because one sire had 13G13G FEZL
alleles, whereas five had 12G13G FEZL alleles in our families
(Fig. 2), we were able to determine the effect of FEZL genotypes
in the six sires on SCS of their offspring. As shown in Table 2,
one 12G allele was sufficient to decrease SCS. We also randomly
collected and typed 492 samples derived from 217 sires in the
Tokachi county area. Although these samples for animals born
during 1997–2001 did not include 12G12G FEZL cattle, the
average SCS of 13G13G FEZL cattle was higher than that of
cattle with 12G13G FEZL (Table 2), supporting the observa-
tions in our half-sibling families. Together, these results indicate
that 12G FEZL influences resistance to clinical mastitis.
Mastitis Induces FEZL. Consistent with a role for FEZL as a
transcription factor that regulates forebrain development, bo-
vine FEZL was expressed strongly in the brain and weakly in the
mammary gland (Fig. 3A). Nevertheless, FEZL expression is
greater in the quarter affected with mastitis, confirmed by the
California Mastitis Test, than in the cured quarter of the same
cattle (Fig. 3A). Because it is possible that infection enhances
FEZL expression in the mammary gland, we hypothesized that
FEZL has an important role in antimicrobial response and that
the polymorphism we described affects function.
FEZL Binds GCAG.To elucidate the effect of the polymorphism on
function, V5-tagged FEZL were transfected into monkey
kidney COS-7 cells or human breast cancer-derived OCUB-M
cells. Both 12G and 13G FEZL localized to the nucleus (Fig. 8,
which is published as supporting information on the PNAS web
site), indicating that the polymorphism does not affect protein
localization.
In many transcription factors, the zinc fingers mediate binding
to promoter elements of their target genes (17). To determine
the optimal binding sequences for the FEZL protein, we per-
formed chromatin immunoprecipitation assays of cells trans-
fected with His-tagged FEZL. Comparison of the selected
sequences by anti-His antibody yielded an optimal binding site of
GCAG, and there was no difference between the 12G and 13G
FEZL consensus in COS-7 and OCUB-M cells (Fig. 9, which is
published as supporting information on the PNAS web site). Gel
mobility shift and competition experiments showed that binding
was abolished by coincubation with unlabeled consensus (lanes
4 and 9 in Fig. 10, which is published as supporting information
on the PNAS web site) but not by AP2 (lanes 5 and 10 in Fig. 10),
demonstrating that DNA binding activities of 12G and 13G
FEZL are similar.
FEZL Activates SEMA5A. Androgen receptors contain a glycine
stretch, and its complete deletion reduces transactivation in vitro
(18), suggesting that the length of the glycine stretch in FEZL
might affect its transcription activity. To compare 12G and 13G
FEZL transcription activities, we selected the first (SEMA5A1)
and second (SEMA5A2) introns of SEMA5A as binding se-
Table 1. SCS of the half-sibling families with the number of
collected samples in parentheses
Sire SCS  1 1  SCS  4 4  SCS Total
Average
SCS  SD
1 163 (16) 1,340 751 (7) 2,254 2.67  1.37
2 215 (65) 1,124 601 (30) 1,940 2.56  1.49
3 62 (51) 418 208 (27) 688 2.55  1.39
4 57 (57) 285 269 (72) 611 2.97  1.60
5 88 (41) 441 183 (23) 712 2.41  1.39
6 67 (67) 203 86 (22) 356 2.28  1.48
Total 652 (297) 3,811 2,098 (181) 6,561 2.60  1.45
Fig. 1. An SCS locus is linked to FEZL. (A) Likelihood of odds score profile by
DISEQ (black) and F-statistic profile by QTLEXPRESS (red) on BTA22 obtained by the
second screening. A dotted line indicates the chromosome-wide threshold of
P 0.01 by QTLEXPRESS. (B) A bacterial artificial chromosome contig. The names
of clones beginning with H were from CHORI-240, names of clones beginning
with Y were from Wagyu, and others were from RPCI-42. Blue dotted lines
indicate human homologue locations.














quences obtained from the chromatin immunoprecipitation
assays (Fig. 11, which is published as supporting information on
the PNAS web site). 12G FEZL induces both the SEMA5A1 and
SEMA5A2 reporters to higher levels than 13G FEZL (Fig. 3B).
12G FEZL stimulates greater SEMA5A expression than 13G
FEZL in OCUB-M cells (Fig. 3C). Conversely, small interfering
RNA (siRNA) targeting FEZL reduces SEMA5A expression
(Fig. 12, which is published as supporting information on the
Fig. 2. Haplotype map of selected samples. Blue and purple boxes indicate homozygous R alleles, and pink and beige boxes indicate homozygous S alleles. Green
boxes indicate sequenced samples, and yellow boxes indicate the 6.2-centimorgan region.
Table 2. The effects of FEZL on SCS
Animals 5  SCS (%) Average SCS  SD P value (t test)
12G12G daughters 892 (8.7) 1.62  1.84 0.0005*
12G13G daughters 18162 (11.1) 2.12  1.98
13G13G daughters 38224 (17.0) 2.56  2.17 0.05**
Daughters from 12G13G sire 4685,950 (7.9) 2.56  1.42
Daughters from 13G13G sire 73611 (12.0) 2.97  1.60 0.000001
12G13G random samples 044 (0) 2.00  0.69
13G13G random samples 4448 (0.9) 2.31  0.89 0.01
*, P value vs. 13G13G daughters. **, P value vs. 12G13G daughters.
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PNAS web site). Moreover, SEMA5A expression is greater in
12G13G FEZL cattle than in 13G13G FEZL cattle, indicating
that SEMA5A is the target of FEZL in vivo (Fig. 13, which is
published as supporting information on the PNAS web site).
Furthermore, mastitis induces SEMA5A expression, demonstrat-
ing that infection enhances SEMA5A through FEZL in vivo (Fig.
13). Thus, the glycine stretch in FEZL appears to influence
transcription activity of SEMA5A after infection.
FEZL Induces TNF- and IL-8 Through SEMA5A. To investigate po-
tential genes that might be induced by SEMA5A, we screened
OCUB-M cells transfected with SEMA5A by microarray anal-
ysis. The candidate genes induced by SEMA5A included nine
genes related to chemotaxis and inflammatoryimmune re-
sponse, but not plexin (PLXN) B3, a gene coding a known
receptor for SEMA5A (ref. 19 and Fig. 14, which is published as
supporting information on the PNAS web site). The induction of
two of the nine genes, TNF- and IL-8, was confirmed by
quantitative RT-PCR (Fig. 4A). In addition, 12G FEZL induced
greater TNF- and IL-8 expression than 13G FEZL (Fig. 4A).
In contrast, RNA interference of FEZL or SEMA5A reduced
TNF- and IL-8 expression (Fig. 12). Impaired TNF- and IL-8
expression controlled by FEZL and SEMA5A could explain
susceptibility of 13G FEZL cattle to mastitis.
Infection Induces FEZL Through TollIL-1-Receptor-Domain-Containing
Adapter Protein-Inducing IFN- (TRIF). Escherichia coli causes
13.9% of mastitis (1). To build a model of mammary glands
infected by Gram-negative bacteria, we conducted quantitative
RT-PCR using OCUB-M cells after LPS treatment. Consistent
with the results in bovine mammary gland (Figs. 3A and 13),
treatment with 10 gml LPS from E. coli induced both FEZL
and SEMA5A expression in OCUB-M cells (Fig. 4B). The
maximum induction was achieved at 6 h, suggesting that FEZL–
SEMA5A signaling is involved in the late phase of the infection.
LPS facilitates the myeloid differentiation primary-response
protein 88 (MyD88)-dependent response in the early phase and
the MyD88-independent response in the late phase through
Toll-like receptor (TLR) 4 (ref. 20 and Fig. 4D). RNA interfer-
ence experiments targeting MyD88, TRIF, and IFN-regulatory
factor (IRF) 3 revealed that both small interfering TRIF and
siIRF3 reduce FEZL and SEMA5A expression 6 h after LPS
treatment whereas siMyD88 does not (Fig. 4C). These observa-
tions indicated that LPS activates FEZL expression in a MyD88-
independent manner through the late phase of infection medi-
ated by TLR4, TRIF, and IRF3 (Fig. 4D).
Discussion
We have presentedmultiple lines of evidence demonstrating that
FEZL is one of the genes responsible for mastitis resistance in
cattle. First, the FEZL region was mapped as a QTL on BTA22
by using six half-sibling families having the same grandsire. It is
important to note that Heyen et al. (21) identified seven putative
QTL for SCS, including two on chromosome 22. Second, the
polymorphism of the length of the glycine stretch of FEZL was
significantly associated with SCS. Third, the length of the glycine
stretch of FEZL impacts its transcription activity, leading to
control of cytokine expression. Our linkage study and cell-based
assay clearly indicated that a single glycine insertion into the
glycine stretch of FEZL has a large effect on its downstream
pathway. In our 1990–1996 samples, the incidence of 13G13G
FEZL homozygotes was 46.9% (224478). In the 1997–2001
samples, it was 91.1% (448492). The incidence of clinical
mastitis in the Tokachi County area has increased from 19.7–
22.5% during 1997–1998 to 24.8–28.2% during 2002–2003 (22),
suggesting that changes in FEZL genotypes might have an
impact on the incidence of clinical mastitis.
Many studies have documented the importance of neutrophil
migration for innate immunity. Neutrophils are highly effective
phagocytes for clearing infecting bacterial pathogens from host
tissue (23). The number of neutrophils migrating to the site of
infection has been associated with the production of IL-8 (24).
TNF- induces IL-8 expression in the late phase of infection
(25), and the IL-8 receptor is also involved in transepithelial
neutrophil migration (26). Moreover, lung-specific transgenic
mice with KC, one of the IL-8 homologues in the mouse, are
resistant to Klebsiella pneumoniae infection (27). On the other
hand, IL-8 receptor knockout mice are susceptible to acute
experimental pyelonephritis (28). Thus, the ability of FEZL to
promote TNF- and IL-8 expression through SEMA5A trig-
gered by LPS represents a plausible mechanism to explain the
enhanced antimicrobial activity of FEZL-expressing cells. In
addition, we identified FEZL as a QTL influencing mastitis
resistance. Our results suggest that FEZL is positioned at the
crossroads of neuronal development and innate immunity.
Materials and Methods
Mapping. Genomic DNA was isolated from blood by using
NA-100048S (Kurabo, Tokyo). Fluorescently labeled (CA)n
microsatellite markers were selected from the Shirakawa–U.S.
Department of Agriculture genetic map (29). Genotyping was
performed by using the ABI 3700 sequencer, GENESCAN V.3.1.2,
and GENOTYPER V.2.1 (Applied Biosystems). Linkage analysis
Fig. 3. Mastitis induces SEMA5A through FEZL. (A) FEZL expression. Results
are means of quantity relative to brain. Green bars indicate the mean (n 3)
from the same cattle, and red and blue bars indicate the mean (n  3) from
other cattle with mastitis. The orange bar indicates the mean SEM (n 54)
from 18 randomly collected cattle with unknown status. Symbols denote
statistically significant results as determined by Student’s t test (§§, P 0.0005;
§§§, P  0.0001). (B) Luciferase assay of FEZL with SEMA5A1 (red) and
SEMA5A2 (blue). Results are means  SEM of relative activity to COS7 cells
transfected without FEZL. Asterisks denote statistically significant results as
determined by Student’s t test (**, P  0.01; ***, P  0.005). (C) SEMA5A
expression in OCUB-M cells transfected with FEZL. Results are means  SEM
(n  9; three experiments) of quantity relative to OCUB-M cells transfected
without FEZL after adjusting for the FEZL expression level. Asterisks denote
statistically significant results as determined by Student’s t test (*, P  0.05;
***, P  0.005).














was done with DISEQ (30) and QTLEXPRESS (31). To construct a
bacterial artificial chromosome contig, we screened the bovine
CHORI-240, RPCI-42, and Wagyu bacterial artificial chromo-
some libraries (32, 33) by PCR. Sequence analysis was conducted
by SEQUENCHER V.4.1 (Gene Codes, Ann Arbor, MI).
Transfection. Bovine FEZL coding sequences were derived by
RT-PCR for exons 1–4 of FEZL by using primers CCTCGGCG-
GCCACCTCTTCC (forward) and GGAATTCCAGCTCTG-
CACTGTCCGAGTC (reverse) and by genomic PCR for exon 1,
including the glycine stretch of resistant or susceptible FEZL
using primers GGGGATCCGCGCCATGGCAAGCTC (for-
ward) and TGACGCCGCCGCGCTCAGCA (reverse). These
coding sequences were connected by BglI (TOYOBO, Osaka)
and T4 ligase (New England Biolabs, Beverly, MA). The hu-
man SEMA5A coding sequence was derived by RT-PCR using
primers AAAAAGCAGGCTCCATGAAGGGAACCTGTG-
TTATAGCATG (forward) and AGAAAGCTGGGTAGTA-
CTCATCATAATTATTGAGATCTGTAAAGTA (reverse)
and human fetal kidney Marathon-ready cDNA (BD Bio-
sciences). Full-length bovine FEZL or human SEMA5A cDNAs
were cloned into pcDNA-DEST40 (Invitrogen) to produce
V5-His-tagged protein. COS-7 and OCUB-M (34) cells were
provided by the RIKENBio-Resource Center (Tsukuba, Japan).
Transfection was done with Lipofectamine 2000 (Invitrogen) for
24 h for COS-7 and 48 h for OCUB-M cells. Immunofluores-
cence was performed by using f luorescein isothiocyanate-
conjugated V5 antibody (Invitrogen), Vectorshield (Vector Lab-
oratories), Axioplan 2, and Metasystems Isis (Carl Zeiss,
Oberkochen, Germany).
Chromatin Immunoprecipitation Assays. Cells transfected with
FEZL were processed with the chromatin immunoprecipitation
assay kit (Upstate Biotechnology, Lake Placid, NY). Sequences
selected by anti-His (C-terminal) antibody (Invitrogen) were
amplified in ligation-mediated PCR (35), and the consensus was
determined by comparing 20 sequences for 12G FEZL and 16
sequences for 13G FEZL in COS-7 cells and 27 sequences for
12G FEZL and 21 sequences for 13G FEZL in OCUB-M cells.
Gel Mobility Shift Assay. Nuclear protein of COS-7 cells trans-
fected with FEZL was extracted by using the CelLytic NuClear
extraction kit (Sigma) and examined by the gel shift assay system
(Promega). Protein concentration was measured by Bio-Rad
protein assay using BSA as the standard.
Luciferase Assay. Luciferase assay was performed by using a
FEZL- pcDNA-DEST40 vector, SEMA5A-pGL3 (R2.2) basic
vector, and pRL-TK vector as an internal control (ratio of
10:10:1) based on the dual-luciferase reporter assay system
(Promega). Assays were repeated five times each, and the
Fig. 4. FEZL is in the TLR4 signaling pathways. (A) TNF- (red) and IL-8 (blue) expression in OCUB-M cells transfected with SEMA5A or FEZL. Results are means
SEM (n 9; three experiments) of quantity relative to OCUB-M cells transfected without constructs after adjusting for the FEZL expression level. Symbols denote
statistically significant results as determined by Student’s t test (*, P 0.05; **, P 0.01; ***, P 0.005; §, P 0.001). (B) FEZL (red) and SEMA5A (blue) expression
in OCUB-M cells treated by 10 gml LPS. Results are means (n 3), and asterisks denote statistically significant results as determined by Student’s t test (*, P
0.05; **, P  0.01). (C) MyD88, TRIF, IRF3, FEZL, and SEMA5A expression in OCUB-M cells transfected with siRNAs. Results are means  SEM (n  9; three
experiments) of quantity relative to OCUB-M cells transfected without constructs. Symbols denote statistically significant results as determined by Student’s t
test (*, P 0.05; **, P 0.01; ***, P 0.005; §§§, P 0.0001). (D) Schematic diagram of the TLR4 signaling pathways. Red arrows indicate the pathway revealed
by this work.
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average measurements were calculated after subtracting the
background signals based on 10 readings for Renilla luciferase.
Microarray Analysis. RNA of OCUB-M cells transfected with
SEMA5A was extracted by using an RNeasy Mini kit (Qiagen,
Valencia, CA) and hybridized to Human Genome U133 Plus 2.0
GeneChips according to standard Affymetrix (Santa Clara, CA)
protocols. Assays were duplicated.
Real-Time Quantitative RT-PCR.RNA of bovine brain, kidney, lung,
mammary gland, ovary, and transfected OCUB-M cells was
extracted by using TRIzol (Invitrogen). Quantitative RT-PCR
was conducted by using an ABI 7900HT sequence detection
system using the comparative Ct method and glyceraldehyde-3-
phosphate dehydrogenases (GAPD) as internal controls (Ap-
plied Biosystems). RT-PCR with siRNAs was conducted with
RNA extracted 6 h after 10 gml LPS treatment. LPS was
purchased from Sigma. Primers for RT-PCR are CTACAAGC-
CCTTCGTCTGTGAAT (forward), GCTGTGGGTCAGCTT-
GTGATT (reverse), and ACCAAAAAGGGAACTAC (probe)
for bovine FEZL; TGTGGGACCAACGCTTTCA (forward),
TCATGGATCTCCGTCAGGTTACT (reverse), and CCTGT-
CTGCACGAACCGCACGTT (probe) for bovine SEMA5A;
and GCCCTCAACGACCACTTTGT (forward), CCTGTT-
GCTGTAGCCAAATTCA (reverse), and AAGCTCATTTC-
CTGGTACGA (probe) for bovine GAPD. Sequences of prim-
ers for human FEZL, SEMA5A, TNF, IL-8, MyD88, TRIF,
IRF3, and GAPD could be purchased as TaqMan Gene Expres-
sion Assays (PN: Hs00375188m1, Hs00187651m1, 4327055M,
4327042M, Hs00182082m1, Hs00706140s1, Hs00155574m1,
and 4326317E, Applied Biosystems). Sequences for siRNAs for
human MyD88 could be purchased as Stealth RNAi (PN:
46-1564 and 46-1565, Invitrogen). Sequences for siRNAs for
human FEZL, SEMA5A, TRIF, and IRF3 could be purchased
as siGENOM SMARTpool reagent (PN: M-016985-00,
M-019490-00, M-012833-00, and M-006875-01; Dharmacon,
Lafayette, CO).
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